NASDAQ$ADAPY
Adaptimmune Therapeutics Plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Adaptimmune reported its Q1 2024 financial results and business updates.
Adaptimmune reported a revenue of $5.7 million for the first quarter ended March 31, 2024, compared to $47.6 million for the same period in 2023. The company's cash and cash equivalents were $140.7 million as of March 31, 2024. Adaptimmune believes its cash runway will extend into late 2025, supported by anticipated revenues from afami-cel and other income sources.
- Afami-cel BLA was accepted by the U.S. FDA for advanced synovial sarcoma treatment with priority review and a PDUFA date of August 4th, 2024.
- Commercial and manufacturing infrastructure is in place to support the afami-cel commercial launch upon approval.
- Data from the SPEARHEAD-1 pivotal trial with afami-cel was published in The Lancet.
- Cash runway extends into late 2025, supported by current cash, afami-cel revenues, and other income sources.
Headline financials
Revenue & EPS history
Adaptimmune · Revenue · Quarterly
$5.68M
Revenue by segment
Adaptimmune · $1.42M total across 1 segment · Q4 2021
- Development revenue$1.42M—100.0%
Forward guidance
The company believes that its existing cash, cash equivalents and marketable securities, together with anticipated revenues from the launch of afami-cel, expected future income from partners and other non-dilutive capital sources including the Company’s new debt facility with Hercules Capital announced earlier today, will fund the Company’s current operations into late 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-3.0%
Avg return
Earnings day
-7.9%
Avg return
5 days after
-3.2%
Avg return
30 days after
37%
16 / 43 earnings
Positive
+26.5%
Q3 2022
Best reaction
-37.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -90.0% | — | |
| Q3 2025 | +0.0% | -90.0% | — | |
| Q2 2025 | +1.3% | -9.1% | -27.3% | |
| Q1 2025 | +4.7% | +0.7% | -7.9% | |
| Q4 2024 | -37.7% | -44.3% | -47.0% | |
| Q3 2024 | -25.5% | +12.5% | -1.9% | |
| Q2 2024 | +5.8% | +8.8% | +8.8% | |
| Q1 2024 | +4.3% | -4.3% | -12.2% | |
| Q4 2023 | +19.2% | +5.5% | -6.2% | |
| Q3 2023 | -8.2% | -20.6% | -8.6% | |
| Q2 2023 | -5.2% | -8.7% | -14.5% | |
| Q1 2023 | +2.2% | -1.5% | -27.4% | |
| Q4 2022 | -29.0% | -36.4% | -40.3% | |
| Q3 2022 | +26.5% | +51.2% | +6.0% | |
| Q2 2022 | +20.6% | +14.4% | +4.1% | |
| Q1 2022 | -8.8% | -17.5% | -0.6% | |
| Q4 2021 | -4.9% | +19.8% | +7.7% | |
| Q3 2021 | +0.0% | +0.7% | -34.6% | |
| Q2 2021 | +2.3% | +14.3% | +79.1% | |
| Q1 2021 | -6.6% | -6.7% | -7.4% | |
| Q4 2020 | -7.5% | -9.3% | -14.4% | |
| Q3 2020 | -1.7% | -7.9% | -15.7% | |
| Q2 2020 | -8.5% | -6.8% | -8.9% | |
| Q1 2020 | +2.4% | +13.9% | +118.9% | |
| Q4 2019 | +3.1% | -0.3% | -18.8% | |
| Q3 2019 | -18.2% | -25.6% | +1.8% | |
| Q2 2019 | -23.7% | -36.0% | -51.1% | |
| Q1 2019 | -6.9% | -9.1% | -18.1% | |
| Q4 2018 | -9.7% | -12.1% | -11.5% | |
| Q3 2018 | -6.7% | -13.3% | -19.4% | |
| Q2 2018 | -8.7% | -8.3% | +19.0% | |
| Q1 2018 | +2.6% | -0.5% | -1.2% | |
| Q4 2017 | +20.1% | +12.5% | +35.2% | |
| Q3 2017 | +8.8% | +8.8% | +7.9% | |
| Q2 2017 | +1.7% | +2.4% | +23.2% | |
| Q1 2017 | -3.0% | +4.1% | +0.6% | |
| Q3 2016 | +2.9% | +0.0% | -14.6% | |
| Q2 2016 | -7.2% | -12.6% | -16.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q4 2015 | -10.5% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q2 2015 | -0.8% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro